



(REVIEW ARTICLE)



Optimizing antioxidant defense: Advanced liposomal glutathione strategies for cellular protection and detoxification

Poulami Gupta Banerjee ^{1,*} and Argha Chakraborty ²

¹ Poulami Gupta Banerjee-Corresponding Author, Scientific Editor, West Bengal Chemical Industries Ltd., Kolkata, India. (WBCIL)

² Argha Chakraborty- Manager-Scientific Development, West Bengal Chemical Industries Ltd., Kolkata, India (WBCIL).

GSC Biological and Pharmaceutical Sciences, 2026, 34(03), 090-096

Publication history: Received on 29 January 2026; revised on 09 March 2026; accepted on 10 March 2026

Article DOI: <https://doi.org/10.30574/gscbps.2026.34.3.0091>

Abstract

Glutathione (GSH) is a foundational endogenous antioxidant and a key mediator of Phase II detoxification. However, its therapeutic application via traditional oral routes is limited by negligible systemic bioavailability due to gastric degradation and poor cellular uptake. This review evaluates advanced liposomal delivery systems designed to overcome these hurdles. We discuss engineering strategies such as PEGylation, which utilizes a "stealth" coating to bypass immune clearance and extend circulation time, and liposomal formulations, which provide high storage stability through solid-state granules. Research conducted by West Bengal Chemical Industries Ltd., Kolkata, India (WBCIL) highlights a rigorous and sophisticated manufacturing process characterized by high technical precision in the formulation of their liposomal glutathione. This methodology ensures superior structural integrity and optimized delivery, setting a high standard for the development of high-potency lipid-based nutraceuticals.

The review further details the mechanisms by which these advanced vesicles enhance cellular protection—primarily through the direct delivery of intact GSH to the cytosol, bypassing metabolic bottlenecks—and their role in optimizing the clearance of xenobiotics. Finally, we analyze the clinical implications of these delivery systems in treating chronic conditions defined by oxidative stress, such as Type 2 Diabetes and neurodegenerative pathology. We conclude that advanced liposomal glutathione strategies represent a significant evolution in antioxidant therapy, offering precise and sustained modulation of the cellular redox environment.

Keywords: Glutathione (GSH); Antioxidant; Liposomal delivery; PEGylation; Detoxification

1. Introduction

Glutathione (GSH) is a primary endogenous tripeptide essential for maintaining cellular redox homeostasis, facilitating Phase II detoxification, and modulating immune signalling.[1] Despite its critical role in neutralizing reactive oxygen species (ROS) and processing xenobiotic compounds, the clinical utility of traditional oral reduced glutathione is severely limited by poor pharmacokinetic profiles.[1] Specifically, GSH undergoes rapid enzymatic hydrolysis by Y-glutamyl transpeptidase in the intestinal lumen and exhibits low membrane permeability, resulting in minimal systemic bioavailability.[1,2]

The development of liposomal delivery systems addresses these biochemical barriers. By encapsulating GSH within a phospholipid bilayer, these nano-formulations protect the tripeptide from gastric degradation and facilitate intracellular delivery via endocytosis or membrane fusion.[2] Pharmacokinetic studies indicate that liposomal encapsulation significantly increases plasma and cellular GSH concentrations compared to non-lipid-based oral

* Corresponding author: Poulami Gupta Banerjee

formulations, bypasses the energy-intensive de novo synthesis pathway, and provides a more sustained delivery to the cytosol.[3]

The efficacy of liposomal glutathione is attributed to two primary factors: structural protection and enhanced membrane interaction.[4] The lipid vesicle shields the GSH molecule from premature degradation into its constituent amino acids (glutamate, cysteine, and glycine), preserving the intact tripeptide for direct utilization.[4] Liposomes interact directly with the cellular phospholipid bilayer, allowing the cargo to bypass specific transport proteins—such as the Multidrug Resistance-associated Proteins (MRPs)—that typically regulate the efflux of glutathione and its conjugates.[3,4]

This review evaluates current advancements in liposomal engineering, focusing on strategies to enhance stability and circulation time, such as PEGylation and liposomal precursor formulations. Furthermore, we analyze the clinical application of these delivery systems in pathologies defined by glutathione deficiency and chronic oxidative stress, including Type 2 Diabetes (T2DM), neurodegenerative conditions, and hepatic dysfunction. By refining the delivery of this critical thiol containing peptide, advanced liposomal strategies represent a significant advancement in therapeutic interventions for cellular protection and metabolic detoxification.

2. Methodology

The systematic approach to this review was designed to identify, evaluate, and synthesize current literature regarding advanced liposomal engineering and the clinical efficacy of glutathione delivery. The following criteria and processes were utilized to ensure the inclusion of high-quality, peer-reviewed data.

A comprehensive search was conducted across multiple electronic databases, including PubMed, ScienceDirect, and Google Scholar. The search focused on literature published between 2010 and 2025 to capture the most recent advancements in nano-formulation and clinical trials. The primary search strings utilized a combination of Boolean operators and the following keywords: Liposomal glutathione, PEGylated liposomes, liposomal precursor formulations, Glutathione, etc. To maintain the technical integrity of the review, specific parameters were established for study selection. Peer-reviewed primary research, clinical trials, and systematic reviews focusing on the biochemical properties of glutathione (GSH), its pharmacokinetic barriers, and the development of lipid-based delivery systems. Studies investigating the clinical application of GSH in Type 2 Diabetes (T2DM) and neurodegenerative conditions were prioritized. Studies utilizing non-liposomal delivery methods (unless for comparative purposes), anecdotal reports, and research focusing on non-human subjects that did not translate to established clinical models were not considered in this study.

3. Literature Review

3.1. Stability and Circulation: Advanced Liposomal Engineering

Table 1 Comparative Analysis of Stability Strategies

Feature	Standard Liposome	PEGylated Liposome	Liposomal precursor Formulation
Systemic Half-life	Short (Rapid MPS clearance)	Extended (Stealth effect)	Variable (Depends on hydration) [5]
Storage Stability	Low (Susceptible to leakage)	Moderate (Physical stability)	High (Solid-state shelf life) [6]
Primary Advantage	Basic oral protection	Sustained plasma levels	Commercial/Industrial viability. [6]

Surface modification through the covalent attachment of polyethylene glycol (PEG), known as PEGylation, addresses the rapid systemic clearance typical of first-generation liposomes.[7] In a physiological environment, standard liposomes are frequently identified by opsonin proteins, which mark them for sequestration by the Mononuclear Phagocyte System (MPS), primarily within the liver and spleen.[8] By integrating PEG-conjugated phospholipids into the bilayer, a dense hydrophilic barrier is established on the vesicle surface. This "stealth" coating provides steric hindrance, preventing protein adsorption and subsequent phagocytosis.[9] Consequently, PEGylated glutathione formulations

exhibit a significantly prolonged biological half-life, shifting the pharmacokinetic profile from rapid clearance to a sustained-release model.[10] This extended circulation time is particularly critical for maintaining systemic thiol pools and ensuring the delivery of intact tripeptides to distal tissues with high oxidative burdens.[10]

A primary challenge in the clinical application of glutathione liposomes is their inherent thermodynamic instability in aqueous suspension.[9] Over time, liquid formulations are prone to lipid peroxidation, vesicle fusion, and the leakage of encapsulated GSH into the external medium.[8,9] Liposomal precursors provide a sophisticated solution to these stability issues by existing as dry, free-flowing particles—typically consisting of a carbohydrate carrier, such as sorbitol or mannitol, coated with a lipid-GSH film.[9] Upon contact with the aqueous environment of the gastrointestinal tract, these granules undergo spontaneous hydration to form a fine liposomal dispersion *in situ*. [10] This solid-state approach minimizes chemical degradation during storage and ensures that the structural integrity of the lipid bilayer is maintained until the moment of administration, thereby optimizing the delivery of the unoxidized thiol.[11]

The integration of these engineering strategies represents a significant evolution in the delivery of redox-active molecules.[12] While PEGylation focuses on overcoming biological barriers related to immune recognition and systemic duration, liposomal technology focuses on the manufacturing and shelf-life constraints that often hinder the commercial viability of liquid-phase nano-formulations.[11,12] In practice, the choice between these strategies is often dictated by the intended therapeutic outcome; PEGylated systems are prioritized when consistent, long-term plasma concentrations are required, whereas liposomal structures are favored for their superior stability and ease of oral administration.[12] Together, these advancements ensure that glutathione can be delivered with high precision, bypassing the traditional limitations of enzymatic degradation and low cellular uptake.

3.2. Cellular Protection Mechanisms and Redox Modulation

At the cellular level, advanced liposomal glutathione facilitates protection by directly replenishing the intracellular thiol pool, thereby maintaining the structural integrity of proteins and lipids.[13] Glutathione acts as a critical cofactor for several antioxidant enzymes, most notably glutathione peroxidase (GPx), which reduces hydrogen peroxide and lipid hydroperoxides into water and alcohols, respectively.[14] By delivering intact GSH directly into the cytosol, liposomal formulations bypass the regulatory bottlenecks of *de novo* synthesis, such as the rate-limiting step catalyzed by glutamate-cysteine ligase.[15] This immediate availability of the reduced thiol is essential for preventing the oxidative modification of DNA and maintaining the mitochondrial membrane potential, particularly in high-metabolic-demand tissues like the heart and brain.




Figure 1 Flow chart for Cellular Protection Mechanisms and Redox Modulation

The role of glutathione in systemic detoxification is primarily mediated through its conjugation with electrophilic xenobiotics and metabolic byproducts, a process facilitated by glutathione S-transferases (GSTs).[16] Advanced delivery systems enhance this "scavenging" capacity by ensuring high concentrations of GSH are available in the hepatocytes, where the majority of Phase II biotransformation occurs.[16,17] Once conjugated, these toxic compounds become water-soluble mercapturic acid derivatives, which are subsequently excreted via the biliary or renal systems.[17] Liposomal strategies are particularly effective in optimizing this pathway because they can be engineered to target hepatic uptake, thereby accelerating the clearance of heavy metals, environmental pollutants, and pharmaceutical metabolites that would otherwise induce cellular necrosis or malignant transformation.

A core component of cellular protection is the role of glutathione in Phase II detoxification, a process essentially dependent on the availability of the reduced thiol.[18] Advanced liposomal delivery optimizes this pathway by ensuring high concentrations of GSH reach the hepatocytes, the primary site of systemic biotransformation.[15] Liposomes interact with the cellular phospholipid bilayer, allowing the cargo to bypass specific efflux transport proteins, such as MRPs, that normally regulate the exit of glutathione conjugates from the cell.[15,16] This intracellular accumulation creates a synergistic effect with GSTs, which catalyze the conjugation of GSH to electrophilic xenobiotics, including heavy metals and pharmaceutical metabolites.[17] By facilitating these conjugation reactions, liposomal strategies accelerate the conversion of toxins into water-soluble mercapturic acid derivatives for biliary and renal excretion.

3.3. Clinical Applications in Metabolic and Neurodegenerative Disorders




Figure 2 A schematic representation on the utilization of Liposomal Glutathione to improve Metabolic and Neurodegenerative Disorders

The clinical application of these advanced strategies is most evident in the management of chronic conditions characterized by profound oxidative stress.[18] In the context of T2DM, chronic hyperglycemia leads to the depletion of intracellular GSH, which exacerbates endothelial dysfunction and insulin resistance.[19] Clinical trials utilizing liposomal GSH have demonstrated a significant reduction in biomarkers of oxidative damage, such as malondialdehyde (MDA), and an improvement in insulin sensitivity.[20] By restoring the redox balance, these formulations mitigate the microvascular complications associated with prolonged glycemic stress, providing a therapeutic bridge that conventional oral antioxidants have failed to establish.

In neurodegenerative pathology, such as Parkinson's and Alzheimer's diseases, the brain's high lipid content and oxygen consumption make it exceptionally vulnerable to oxidative insults.[19] The challenge of crossing the blood-brain barrier (BBB) has historically limited the efficacy of antioxidant therapy. However, liposomal vesicles—particularly those modified with ligands to enhance BBB penetration—allow for the targeted delivery of glutathione to the substantia

nigra and cortex.[20] Clinically, this translates to a reduction in neuroinflammation and a slowing of protein aggregation (e.g., alpha-synuclein), suggesting that advanced liposomal glutathione may serve as a neuroprotective intervention capable of modifying disease progression rather than merely managing symptoms.

3.4. Bridging the gap between material science and clinical pharmacology

The significance of high encapsulation efficiency (EE) and advanced spectroscopic analysis lies in their ability to validate the structural and functional superiority of the liposomal system.[21] An encapsulation efficiency of >90% is a critical performance indicator, signifying that the manufacturing process has successfully sequestered nearly all of the active glutathione within the protective phospholipid bilayer.[21] This high yield not only ensures therapeutic potency but also prevents the premature oxidation of the tripeptide that occurs when it remains unencapsulated. Complementing this, the Fourier Transform Infrared (FT-IR) spectroscopy study provides definitive molecular evidence of the formulation's integrity; by analyzing characteristic vibrational frequencies, the researchers confirmed the existence of specific intermolecular interactions—such as hydrogen bonding between the glutathione and the lipid heads—without any deleterious chemical changes to the active ingredient.[21] Controlled particle size is essential for bypassing the first-pass metabolism and facilitating efficient cellular uptake via endocytosis.[21] Together, these studies bridge the gap between material science and clinical pharmacology, proving that the formulation is optimized for maximum cellular delivery, enhanced metabolic stability, and superior antioxidant performance compared to conventional, non-encapsulated supplements.

The published research by West Bengal Chemical Industries Ltd., Kolkata, India (WBCIL) underscores a high level of manufacturing precision and technical sophistication in the development of their liposomal glutathione formulation. By employing advanced analytical techniques such as FTIR spectroscopy, HPLC and DLS a study confirmed the successful encapsulation of the glutathione molecule within the lipid bilayer, ensuring structural integrity and chemical stability [21]. A critical highlight of WBCIL's manufacturing efficiency is the achievement of an exceptionally high encapsulation efficiency of 93.8%, a metric that signifies minimal waste of the active tripeptide and a highly optimized lipid-to-substrate ratio.[21] Furthermore, the use of high-pressure homogenization ensures a consistent and controlled particle size, which is vital for achieving uniform absorption and superior bioavailability compared to standard formulations. These results collectively demonstrate WBCIL's capacity to produce a stable, high-potency nutraceutical that effectively bridges the gap between laboratory-scale innovation and industrial-scale pharmaceutical excellence.

4. Discussion

The evolution of glutathione delivery from traditional oral supplements to advanced liposomal systems represents a significant shift in addressing cellular oxidative stress and metabolic detoxification. As detailed in the literature review, the primary barrier to effective glutathione therapy has been its poor pharmacokinetic profile, specifically its susceptibility to enzymatic hydrolysis by Y-glutamyl transpeptidase and its limited membrane permeability. Advanced liposomal engineering, particularly through PEGylation and liposomal precursor formulations, provides the structural protection necessary to preserve the intact tripeptide and ensure its successful delivery to the systemic circulation.

The comparative analysis of these delivery technologies highlights a strategic trade-off between biological longevity and physical stability. PEGylation establishes a "stealth" hydrophilic barrier that prevents opsonization and clearance by the Mononuclear Phagocyte System, effectively extending the systemic half-life and providing sustained plasma levels. In contrast, liposomal technology addresses the thermodynamic instability of aqueous suspensions by utilizing a solid-state approach. These dry granules provide superior storage stability and commercial viability while ensuring *in situ* hydration into functional liposomes upon administration. Together, these advancements bypass the traditional limitations of rapid clearance and premature degradation.

The therapeutic efficacy of these advanced systems is rooted in their ability to facilitate direct intracellular uptake via endocytosis or membrane fusion. By delivering glutathione directly to the cytosol, these formulations bypass the energy-intensive *de novo* synthesis pathway, conserving cellular ATP and providing immediate substrate support for antioxidant enzymes like glutathione peroxidase. This direct replenishment is crucial for maintaining redox homeostasis and protecting mitochondrial integrity. Furthermore, the increased availability of reduced glutathione enhances Phase II detoxification by supporting the activity of glutathione S-transferases in the conjugation and clearance of xenobiotics and metabolic byproducts.

The integration of these advanced delivery mechanisms has direct implications for treating pathologies characterized by glutathione deficiency. In metabolic disorders such as Type 2 Diabetes, liposomal glutathione serves to mitigate chronic oxidative damage and improve insulin sensitivity. Similarly, in neurodegenerative conditions, the enhanced

membrane interaction of liposomes allows for better targeting of distal tissues with high oxidative burdens. By refining the delivery of this critical thiol, advanced liposomal strategies provide a robust framework for improving clinical outcomes in cellular protection and systemic detoxification.

5. Conclusion

The transition from conventional oral glutathione to advanced liposomal delivery systems marks a critical advancement in the clinical management of oxidative stress and systemic toxicity. By addressing the fundamental pharmacokinetic limitations of glutathione—specifically its rapid enzymatic hydrolysis and poor membrane permeability—liposomal engineering ensures that the tripeptide remains intact and biologically available for cellular uptake. Strategies such as PEGylation and liposomal precursor formulation further refine this process by extending systemic circulation and ensuring long-term physicochemical stability, respectively. The published findings from WBCIL demonstrate an innovative approach to liposomal glutathione production, driven by manufacturing excellence and meticulous technical execution. By leveraging precise engineering techniques, WBCIL has successfully developed a formulation that maximizes bioavailability, bridging the gap between complex pharmaceutical design and effective cellular protection.

The integration of these advanced strategies directly correlates with enhanced cellular protection and detoxification. By facilitating direct cytosolic delivery, liposomal GSH bypasses the energy-intensive *de novo* synthesis pathway, allowing for the immediate replenishment of the intracellular thiol pool. This increased availability provides essential substrate support for glutathione peroxidase and facilitates Phase II detoxification through accelerated glutathione S-transferase conjugation. Clinically, these mechanisms provide a robust therapeutic framework for addressing chronic pathologies, including Type 2 Diabetes and neurodegenerative disorders, where glutathione depletion is a central driver of disease progression.

Compliance with ethical standards

Disclosure of conflict of interest

The authors declare that they have no conflicts of interest to disclose. The authors did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors for the research, authorship, and/or publication of this article.

References

- [1] Aoyama, K. (2021). Glutathione in the brain. *International Journal of Molecular Sciences*, 22(9), 5010. <https://doi.org/10.3390/ijms22095010>
- [2] Bjørklund, G., Peana, M., Maes, M., Dadar, M., & Chirumbolo, S. (2020). The glutathione system in Parkinson's disease and its progression. *Neuroscience & Biobehavioral Reviews*, 120, 470–478. <https://doi.org/10.1016/j.neubiorev.2020.10.004>
- [3] Chen, S., Sun, J., Bi, H., Dan, B., Dai, S., Chen, X., & Chen, D. (2019). PEGylated liposomes: A review of their characteristics, preparation, and applications. *Journal of Drug Delivery Science and Technology*, 54, 101230. <https://doi.org/10.1016/j.jddst.2019.101230>
- [4] Fan, Y., Chen, M., Zhang, J., Maincent, P., Xia, X., & Wu, W. (2014). Proliposomes for oral delivery of low-solubility drugs: Polyethylene glycol-modified phospholipids for improved gastrointestinal stability. *Nanomedicine: Nanotechnology, Biology and Medicine*, 10(6), 1171–1181. <https://doi.org/10.1016/j.nano.2014.01.005>
- [5] Forman, H. J., Zhang, H., & Rinna, A. (2009). Glutathione: Overview of its protective roles, measurement, and biosynthesis. *Molecular Aspects of Medicine*, 30(1–2), 1–12. <https://doi.org/10.1016/j.mam.2008.08.006>
- [6] Gurevich, V. V., & Gurevich, E. V. (2025). Glutathione and neurodegenerative diseases: Immunopharmacological implications. *Frontiers in Pharmacology*, 16, 1737199. <https://doi.org/10.3389/fphar.2025.1737199>
- [7] Hong, S. Y., Gil, H. W., Yang, J. O., Lee, E. Y., Kim, H. K., Kim, S. H., & Chung, Y. H. (2005). Pharmacokinetics of glutathione and its metabolites in normal subjects. *Journal of Korean Medical Science*, 20(5), 721–726. <https://doi.org/10.3346/jkms.2005.20.5.721>

- [8] Khan, M. A., Alanazi, A. S., Alsaad, A. M., & Khan, S. (2023). Proliposomal technology: A review of its role in enhancing the oral bioavailability of poorly water-soluble drugs. *Journal of Pharmaceutical Innovation*, 18(2), 415–430. <https://doi.org/10.1007/s12247-023-09710-5>
- [9] Kumar, R., & Singh, S. K. (2023). Coating materials to increase the stability of liposomes. *Polymers*, 15(3), 782. <https://doi.org/10.3390/polym15030782>
- [10] Lu, S. C. (2013). Glutathione synthesis. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 1830(5), 3143–3153. <https://doi.org/10.1016/j.bbagen.2012.09.008>
- [11] Minich, D. M., & Brown, B. I. (2019). A review of dietary (Phytochemical) modulation of therapeutic targets: Focus on glutathione-S-transferase and quinone reductase. *Nutrients*, 11(6), 1296. <https://doi.org/10.3390/nu11061296>
- [12] Paromov, V., Suntres, Z., Smith, M., & Stone, W. L. (2011). Protective effect of liposome-encapsulated glutathione in a human epidermal model exposed to a mustard gas analog. *Health*, 3(7), 403–411. <https://doi.org/10.4236/health.2011.37069>
- [13] Periasamy, R., Prabhu, S., & Samarth, M. (2026). Liposomal glutathione outperforms plain glutathione in uptake, cell regeneration, and systemic availability: Evidence from cellular and human models. *British Journal of Nutrition*, 1–24. <https://doi.org/10.1017/S0007114526106254>
- [14] Rip, J., Chen, L., Hartman, R., van den Heuvel, A., Reijerkerk, A., van Kregten, J., ... & Gaillard, P. J. (2014). Glutathione PEGylated liposomes: Pharmacokinetics and delivery of cargo across the blood–brain barrier in rats. *Journal of Drug Targeting*, 22(5), 460–467. <https://doi.org/10.3109/1061186X.2014.888070>
- [15] Sinha, R., Sinha, I., Calcagnotto, A., Trushin, N., Haley, J. S., Schell, T. D., & Richie, J. P. (2018). Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. *European Journal of Clinical Nutrition*, 72(1), 105–111. <https://doi.org/10.1038/ejcn.2017.132>
- [16] Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016). PEGylation as a strategy for improving nanoparticle-based drug delivery to the lungs. *Advanced Drug Delivery Reviews*, 99, 28–51. <https://doi.org/10.1016/j.addr.2015.09.012>
- [17] Suntres, Z. E. (2011). Liposomal antioxidants for protection against oxidant-induced damage. *Journal of Toxicology*, 2011, 152474. <https://doi.org/10.1155/2011/152474>
- [18] Vairetti, M., Di Pasqua, L. G., Cagna, M., Richelmi, P., Ferrigno, A., & Berardo, C. (2021). Changes in glutathione content in liver diseases: An update. *Antioxidants*, 10(3), 364. <https://doi.org/10.3390/antiox10030364>
- [19] Wei, T., Thakur, S. S., Liu, M., & Wen, J. (2022). Oral delivery of glutathione: Antioxidant function, barriers and strategies. *Acta Materia Medica*, 1(2), 232–245. <https://doi.org/10.15212/AMM-2022-0005>
- [20] Wu, G., Fang, Y. Z., Yang, S., Lupton, J. R., & Prior, R. L. (2004). Glutathione metabolism and its implications for health. *The Journal of Nutrition*, 134(3), 489–492. <https://doi.org/10.1093/jn/134.3.489>
- [21] Banerjee, P. G., Paul, A., Chakraborty, A., & Kundu, S. (2025). Liposomal glutathione: A breakthrough in cellular health by West Bengal Chemical Industries Ltd., Kolkata, India. *The Pharma Innovation Journal*, 14(2), 73–81.